Endeavor Private Wealth Inc. Acquires New Shares in Amgen Inc. (NASDAQ:AMGN)

Endeavor Private Wealth Inc. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, HoldingsChannel.com reports. The firm bought 576 shares of the medical research company’s stock, valued at approximately $150,000.

Several other large investors also recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new stake in shares of Amgen in the 3rd quarter worth about $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the third quarter valued at about $29,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the second quarter valued at about $30,000. Matrix Trust Co purchased a new position in shares of Amgen during the 3rd quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of Amgen during the 3rd quarter worth approximately $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AMGN shares. Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Royal Bank of Canada cut their target price on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Sanford C. Bernstein started coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective for the company. TD Cowen raised their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Citigroup cut their price target on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $273.44 on Thursday. The business’s 50-day simple moving average is $271.91 and its 200 day simple moving average is $306.43. The company has a market cap of $146.98 billion, a P/E ratio of 35.01, a PEG ratio of 2.79 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the previous year, the company posted $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.48%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.